SEC Form 4 · accession 0001209191-18-019671
Evofem Biosciences, Inc. · EVFM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas G Lynch
Director
Period of report
Mar 12, 2018
Accepted (ET)
Mar 14, 2018 · 6:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001618835
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $7.29 | Mar 12, 2018 | A | 24,691 | A | — | Mar 12, 2028 | Common Stock | 24,691 | 24,691 | D |
| Stock option (right to buy)F2 | $7.29 | Mar 12, 2018 | A | 225,000 | A | — | Mar 12, 2028 | Common Stock | 225,000 | 225,000 | D |
Explanation of responses
- F1The shares of common stock exercisable pursuant to the option will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from March 12, 2018. The option was awarded in connection with Mr. Lynch's board services.
- F2Mr. Lynch acquired a vested interest in one hundred twenty-five thousand (125,000) shares of common stock exercisable pursuant to the option effective as of March 12, 2018. The remaining shares shall vest in a series of twelve (12) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from April 1, 2018. The option was awarded in connection with Mr. Lynch's consulting services provided to the Issuer.
Remarks
The options were granted subject to stockholder approval and will be forfeited if stockholder approval is not obtained within twelve months of the date of grant.